Ultimovacs ASA (Norway) Probability of Future Stock Price Finishing Over 1.64
| ULTI Stock | NOK 1.98 0.05 2.46% |
Ultimovacs |
Ultimovacs ASA Target Price Odds to finish over 1.64
The tendency of Ultimovacs Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above 1.64 in 90 days |
| 1.98 | 90 days | 1.64 | about 84.13 |
Based on a normal probability distribution, the odds of Ultimovacs ASA to stay above 1.64 in 90 days from now is about 84.13 (This Ultimovacs ASA probability density function shows the probability of Ultimovacs Stock to fall within a particular range of prices over 90 days) . Probability of Ultimovacs ASA price to stay between 1.64 and its current price of 1.98 at the end of the 90-day period is about 42.61 .
Assuming the 90 days trading horizon Ultimovacs ASA has a beta of -0.8. This usually implies as returns on the benchmark increase, returns on holding Ultimovacs ASA are expected to decrease at a much lower rate. During a bear market, however, Ultimovacs ASA is likely to outperform the market. Additionally Ultimovacs ASA has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Ultimovacs ASA Price Density |
| Price |
Predictive Modules for Ultimovacs ASA
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Ultimovacs ASA. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Ultimovacs ASA Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Ultimovacs ASA is not an exception. The market had few large corrections towards the Ultimovacs ASA's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Ultimovacs ASA, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Ultimovacs ASA within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.2 | |
β | Beta against Dow Jones | -0.8 | |
σ | Overall volatility | 0.28 | |
Ir | Information ratio | -0.06 |
Ultimovacs ASA Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Ultimovacs ASA for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Ultimovacs ASA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Ultimovacs ASA generated a negative expected return over the last 90 days | |
| Ultimovacs ASA has high historical volatility and very poor performance | |
| Ultimovacs ASA may become a speculative penny stock | |
| Ultimovacs ASA has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (164.72 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ultimovacs ASA has accumulated about 1.85 M in cash with (125.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 48.0% of the company outstanding shares are owned by insiders |
Ultimovacs ASA Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Ultimovacs Stock often depends not only on the future outlook of the current and potential Ultimovacs ASA's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ultimovacs ASA's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 34.2 M | |
| Cash And Short Term Investments | 574.2 M |
Ultimovacs ASA Technical Analysis
Ultimovacs ASA's future price can be derived by breaking down and analyzing its technical indicators over time. Ultimovacs Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Ultimovacs ASA. In general, you should focus on analyzing Ultimovacs Stock price patterns and their correlations with different microeconomic environments and drivers.
Ultimovacs ASA Predictive Forecast Models
Ultimovacs ASA's time-series forecasting models is one of many Ultimovacs ASA's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Ultimovacs ASA's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Ultimovacs ASA
Checking the ongoing alerts about Ultimovacs ASA for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Ultimovacs ASA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Ultimovacs ASA generated a negative expected return over the last 90 days | |
| Ultimovacs ASA has high historical volatility and very poor performance | |
| Ultimovacs ASA may become a speculative penny stock | |
| Ultimovacs ASA has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (164.72 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ultimovacs ASA has accumulated about 1.85 M in cash with (125.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 48.0% of the company outstanding shares are owned by insiders |
Other Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.